Drugs / CHS-1420
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07147257 | Feb → May 2025 | — | Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02489227 | Aug 2015 → May 2016 | psoriasis | Coherus Oncology, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHS-1420 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07147257 ↗ |
| Route | Subcutaneous | “Dose of 40 mg will be subcutaneously administered” NCT07147257 ↗ |